Eli Lilly reports Q2 2026 adjusted EPS of $8.38 versus $6.31 year-over-year, revenue of $22.97B versus estimate of $20.59B, Zepbound revenue of $4.93B versus estimate of $4.64B, and raises full-year revenue guidance to $85.0B–$87.0B from prior $82.0B–$85.0B.
ZeroHedge08/05, 05:46 PM
- 2Q ADJ EPS $8.38 VS. $6.31 Y/Y
- 2Q REV. $22.97B, EST. $20.59B
- 2Q ZEPBOUND REV. $4.93B, EST. $4.64B
- FY REV. $85.0B TO $87.0B, SAW $82.0B TO $85.0B
Figures as quoted by ZeroHedge
Related assets
Coming up for LLY
Explore next
Latest LLY news
Jin1008/17, 07:48 PM
Bloomberg08/13, 05:57 PM
FirstSquawk08/13, 12:08 PM
Berenberg raises Eli Lilly price target to $1,220 from $1,135.